Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | HMGCR | P04035 | 2/20 | 0.58 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.56 |
| ▸ | FABP4 | P15090 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | PADI4 | Q9UM07 | 7/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | AKT2 | P31751 | 1/20 | 0.39 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6283353 | 0.89 | RXRA (0.84) | RXRANR1I2NR4A2PDE4DHMGCR | |
| SCHEMBL6283365 | 0.89 | RXRA (0.84) | RXRANR1I2NR4A2PDE4DHMGCR | |
| SCHEMBL6068355 | 0.85 | PRKAA2 (0.61) | RXRANR1I2NR4A2PDE4DHMGCR | |
| SCHEMBL29275349 | 0.84 | RXRA (0.56) | RXRANR1I2NR4A2PDE4DHMGCR | |
| SCHEMBL1744135 | 0.83 | PRKAA2 (0.67) | RXRANR1I2NR4A2PDE4DHMGCR | |
| SCHEMBL13991530 | 0.83 | RXRA (0.68) | RXRANR1I2NR4A2PDE4DHMGCR | |
| SCHEMBL6284295 | 0.83 | RXRA (0.68) | RXRANR1I2NR4A2PDE4DHMGCR | |
| SCHEMBL6284297 | 0.83 | RXRA (0.68) | RXRANR1I2NR4A2PDE4DHMGCR | |
| SCHEMBL7171504 | 0.82 | RXRA (0.67) | RXRANR1I2NR4A2PDE4DHMGCR | |
| SCHEMBL7171838 | 0.82 | RXRA (0.67) | RXRANR1I2NR4A2PDE4DHMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054853-A1 | Process for producing optically active oxoheptenoic acid ester | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054853-A1 | Process for producing optically active oxoheptenoic acid ester | SQLE, APEH, THOP1 | RXRA 881/4885NR1I2 1630/4885NR4A2 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.